Hepatocellular carcinoma (HCC) represents the second leading cause of cancer-related mortality worldwide, claiming over 700,000 lives annually. The liver's central role in blood filtration and metabolism makes it an attractive target for drug delivery, with lipid nanoparticles (LNPs) showing particular promise due to their natural hepatic tropism. However, LNP efficacy becomes compromised in HCC environments due to inadequate understanding of liver physiology under cancerous

protective antibodies create significant challenges for vaccination programs by interfering with vaccine-induced immune responses, thereby reducing vaccine effectiveness. This interference has been well-documented with whole inactivated virus (WIV) vaccines against SwIAV, creating an urgent need for innovative vaccination strategies that can overcome MDA interference while maintaining protective efficacy. The significance of this research extends beyond swine health, as Sw

This research falls under the broader scientific discipline of molecular biology and cancer therapeutics, specifically within RNA-guided genome editing and precision oncology. CRISPR-Cas13d systems represent a powerful class of RNA-targeting tools that can precisely edit target transcripts with minimal off-target effects. However, their clinical development faces significant challenges. One of these is the limited biostability of conventional linear guide RNAs (lgRNAs) suscep

Max-Planck-Institut für Kohlenforschung: New study reveals stereochemistry of lipid nanoparticles critically influences safety and efficacy in mRNA delivery Nagoya University: Japanese researchers engineered a new lipid nanoparticle that delivers mRNA to cells five times more effectively using cyclic disulfide modifications University of Pennsylvania: Study unlocks safer RNA therapies by reducing harmful inflammation caused by lipid nanoparticles using biodegradable lipids

This research falls under the broader scientific discipline of molecular biology and cancer therapeutics, specifically within RNA-guided genome editing and precision oncology. CRISPR-Cas13d systems represent a powerful class of RNA-targeting tools that can precisely edit target transcripts with minimal off-target effects. However, their clinical development faces significant challenges. One of these is the limited biostability of conventional linear guide RNAs (lgRNAs) suscep

Nagoya University: New cyclic disulfide lipids deliver mRNA five times more effectively for cancer treatment University of Ottawa: Development of nano-sized delivery agents with therapeutic potential beyond messenger function University of Pennsylvania: Chemical modification of ionizable lipids reduces inflammation and boosts mRNA therapeutic effectiveness Academic Journals: Multiple publications on circular guide RNA engineering, CRISPR-Cas13d systems, and advanced LNP ch

This research falls within the rapidly evolving field of cancer immunotherapy and nanomedicine, specifically focusing on cytokine-based therapeutic approaches. The study addresses a critical challenge in IL-12 cytokine therapy - the immunosuppressive feedback mechanisms that limit its therapeutic efficacy1. IL-12 has demonstrated potent antitumor activity in preclinical models by promoting T helper type 1 (TH1) differentiation and enhancing cytotoxic T lymphocyte activity. Ho

We’re excited to announce that PreciGenome will be exhibiting at the CRS 2025 Annual Meeting & Exposition! Join us at booth #406 to discover our latest innovations in lipid nanoparticle (LNP) technology. What we offer: Advanced LNP synthesis instruments for efficient and reproducible nanoparticle production High-quality LNP reagents to support your research and development Comprehensive CRO services tailored for your LNP and drug delivery projects Connect with our

AbbVie: acquires Capstan Therapeutics for up to $2.1 billion, adding targeted LNP (tLNP) in vivo CAR-T technology to its immunology pipeline. CRISPR Therapeutics: Phase 1 data show LNP-delivered CRISPR candidate CTX310 cuts triglycerides and LDL by up to 82% and 86%, respectively. University of Pennsylvania–Genevant (Nature Nanotechnology): PEG-lipid ratio and phospholipid choice fine-tune mRNA-LNP adjuvanticity, guiding vaccine design. Ludwig-Maximilians-Universität Münch

Schematic to explain a dual nanocarrier strategy for enhancing PDAC Tumor Immunity. The schematic illustrates a dual vaccination strategy, hypothesized to enhance the PDAC tumor immunity cycle by integrating endogenous and exogenous vaccination approaches. This strategy employs two distinct nanocarriers to synergistically reinforce CTL activation against PDAC. Endogenous Vaccination: Chemotherapeutic agents such as irinotecan induce ICD, triggering the release of tumor antige

Eli Lilly: Acquired Verve Therapeutics for up to $1.3 billion to advance LNP-based gene editing therapies for cardiovascular disease. Genprex: Presented research on non-viral diabetes gene therapy using lipid nanoparticle delivery system at the American Diabetes Association conference. SNS Insider: Published market report projecting lipid nanoparticles market to reach $2.89 billion by 2032, driven by mRNA technology advances. Nature Nanotechnology: Published study on tailo

Cornell University: Developed PEG-free "stealth" LNPs to reduce immune responses in mRNA vaccines. University of Hawaiʻi/Sungkyunkwan University: Created neutrophil-targeted LNPs to mitigate COVID-19 lung damage. Moderna: Received FDA approval for next-gen COVID-19 vaccine (mNEXSPIKE) using refrigerated LNPs. CRISPR Therapeutics: Reported positive Phase 1 data for LNP-delivered ANGPTL3 gene-editing therapy. University of Pennsylvania: Enhanced T-cell responses in mRNA vac

We're proud to share that the Mayo Clinic Florida’s new RNA Research Facility has chosen the PreciGenome NanoGenerator™ Flex-S as their...

Innorna: Presented new data on mRNA-LNP therapies for PFIC2 and Wilson’s Disease at ASGCT 2025. University of Nottingham, MIT, Sail Biomedicines: Developed cryogenic mass spectrometry to analyze LNP surface structures. Sail Biomedicines: Announced preclinical data on in vivo eRNA CAR-T candidate SAIL-0804 for autoimmune diseases. Arcturus Therapeutics: SWOT analysis highlighted LNP platform advancements and pipeline progress. ResearchAndMarkets.com: Reported mRNA platform

Mana.bio: Presented new data demonstrating AI-driven safety model for lipid nanoparticle tolerability to enhance RNA medicine. Grit Biotechnology: Presented scientific breakthroughs at ASGCT 2025 including LNP-mediated CRISPR/Cas9 gene editing for enhancing tumor-infiltrating lymphocytes. Generation Bio: Reported business highlights including advancement of their cell-targeted lipid nanoparticle (ctLNP) technology for siRNA delivery. Aera Therapeutics: Shifted focus

Efficient and precise delivery of CRISPR/Cas9 components remains one of the critical challenges toward the advancement of gene-editing therapies. Here, we have developed a high-throughput Barcode-Integration Nanoparticle Screen (BINS) method to evaluate a library of 96 lipid nanoparticles (LNPs) for their delivery efficiency across  in vitro  and  in vivo  models.  

This paper contributes to the field of RNA vaccinology, specifically addressing a key challenge in self-amplifying RNA (saRNA) vaccine development. While saRNA vaccines offer advantages over conventional mRNA platforms by providing longer-lasting protection at lower doses, they also trigger undesirable side effects at protective doses. These side effects stem from excessive innate immune activation driven by double-stranded RNA intermediates generated during self-replication.

Excited to announce that PreciGenome will be exhibiting at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in New Orleans, May 13-17, 2025! Join us at Booth #1818 to discover our latest innovations in: Lipid Nanoparticle (LNP) Synthesis Systems: Experience our NanoGenerator™ platform, designed for scalable, reproducible, and cost-effective LNP, liposome, and PLGA nanoparticle production-ideal for applications from early discovery to GMP manufact